title: Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.
authors.forename: Amisha V
authors.initials: AV
authors.lastname: Barochia
authors.forename: Xizhong
authors.initials: X
authors.lastname: Cui
authors.forename: Charles
authors.initials: C
authors.lastname: Natanson
authors.forename: Peter Q
authors.initials: PQ
authors.lastname: Eichacker
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects; D018806:APACHE; D002423:Cause of Death; D003422:Critical Care / Q000379:methods; D016638:Critical Illness / Q000401:mortality / Q000628:therapy; D017052:Hospital Mortality; D007362:Intensive Care Units; D008050:Lipid A / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D011379:Prognosis; D018570:Risk Assessment; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate; D016032:Randomized Controlled Trials as Topic; D015337:Multicenter Studies as Topic; D017322:Clinical Trials, Phase II as Topic
chemical_list: D000893:Anti-Inflammatory Agents; C404742:E5564; D008050:Lipid A